FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013953822> ?p ?o ?g. }

• W3013953822 abstract "OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of intranasal Midazolam compared to syrup Chloral hydrate for procedural sedation in children undergoing Auditory Brainstem evoked Response audiometry (ABR). METHODS: A prospective, randomized, double-blinded placebo controlled trial was carried out in the audiology lab of a tertiary care hospital over a period of 18 months. 82 children between the age group of 1 to 6 years (mean 2 years) irrespective of their developmental maturity, belonging to ASA class I and II who were referred for ABR testing were recruited. Children were randomized to receive either midazolam spray with oral placebo or syrup chloral hydrate with nasal placebo spray. The nasal spray was dosed at 0.5 mg/kg delivered as 100mcg per spray and oral syrup at a dose of 50 mg/kg. Those children who did not show onset of sedation at 30 minutes were administered the second dose at half the initial dose. Randomization was computer generated and allocation concealment was achieved by opaque sequentially numbered sealed envelopes that were employed serially to the participating children. The primary outcome measured were safety which was measured in terms of heart rate, respiratory rate, oxygen saturation and efficacy was measured in terms of level of consciousness (uninterrupted sleep without movement) and successful completion of the procedure. The various secondary outcomes were time to onset of sedation, time to parental separation, nature of parental separation, duration of procedure, parental satisfaction, audiologist’s satisfaction, time to recovery and number of attempts. RESULTS: The trial was completed over a period of 18 months when 41 children were studied in each arm. Both the drugs were found to be safe with no major adverse events. One child who had received Midazolam developed transient hypoxia. It was corrected with appropriate head positioning. Minor side effects noted were sneezing, hiccups and crying. Children on Chloral hydrate had an earlier onset of sedation (66% of children) at or less than 30 minutes as compared to only 33% from the Midazolam group. Developmentally delayed children had an earlier onset of sedation compared to developmentally normal group irrespective of the drug they received. Parental separation was earlier for chloral hydrate group at 20 minutes than for midazolam at 30 minutes. There was no statistically significant difference in the duration of procedure. There was a significant difference noted in the time to recovery (Chloral hydrate children (78 minutes) as compared to Midazolam children (105 minutes). Parental and audiologists satisfaction were higher for Chloral hydrate (95% and 75% respectively) than for Midazolam (49% and 29%). A larger number of patients (80%) slept with the first dose of Chloral hydrate as against Midazolam children who required a second dose. Overall, sedation was successful among 95% of children who received chloral hydrate compared to 51% of children who received Midazolam. Once sedation was achieved, both the drugs were efficacious in maintaining sedation with no intra-procedural interruption in sedation. CONCLUSION: Intranasal Midazolam and oral Chloral hydrate are both safe and efficacious for pediatric procedural sedation in ABR. However, Chloral hydrate had a superior efficacy to intranasal Midazolam with an earlier time to onset of sedation, a faster recovery, better parental and audiologist’s satisfaction and successful sedation even with the first attempt. There was no difference in the duration of the procedure. Developmentally delayed children showed an earlier onset of sedation and faster recovery compared to their normal counterparts irrespective of the drug regimen they received." @default.
• W3013953822 created "2020-04-03" @default.
• W3013953822 creator A5083525535 @default.
• W3013953822 date "2014-04-01" @default.
• W3013953822 modified "2023-09-26" @default.
• W3013953822 title "Comparison of efficacy and safety of intranasal Midazolam with syrup Chloral hydrate for procedural sedation of children undergoing Auditory Brainstem evoked Response audiometry: A Randomized, Double-blinded, Placebo controlled trial" @default.
• W3013953822 hasPublicationYear "2014" @default.
• W3013953822 type Work @default.
• W3013953822 sameAs 3013953822 @default.
• W3013953822 citedByCount "0" @default.
• W3013953822 crossrefType "dissertation" @default.
• W3013953822 hasAuthorship W3013953822A5083525535 @default.
• W3013953822 hasConcept C141071460 @default.
• W3013953822 hasConcept C142724271 @default.
• W3013953822 hasConcept C168563851 @default.
• W3013953822 hasConcept C203014093 @default.
• W3013953822 hasConcept C204243189 @default.
• W3013953822 hasConcept C204787440 @default.
• W3013953822 hasConcept C27081682 @default.
• W3013953822 hasConcept C2776814716 @default.
• W3013953822 hasConcept C2777612814 @default.
• W3013953822 hasConcept C2778000748 @default.
• W3013953822 hasConcept C2778074680 @default.
• W3013953822 hasConcept C2780334268 @default.
• W3013953822 hasConcept C2780493683 @default.
• W3013953822 hasConcept C2780973058 @default.
• W3013953822 hasConcept C42219234 @default.
• W3013953822 hasConcept C43791021 @default.
• W3013953822 hasConcept C548259974 @default.
• W3013953822 hasConcept C71924100 @default.
• W3013953822 hasConcept C85663871 @default.
• W3013953822 hasConceptScore W3013953822C141071460 @default.
• W3013953822 hasConceptScore W3013953822C142724271 @default.
• W3013953822 hasConceptScore W3013953822C168563851 @default.
• W3013953822 hasConceptScore W3013953822C203014093 @default.
• W3013953822 hasConceptScore W3013953822C204243189 @default.
• W3013953822 hasConceptScore W3013953822C204787440 @default.
• W3013953822 hasConceptScore W3013953822C27081682 @default.
• W3013953822 hasConceptScore W3013953822C2776814716 @default.
• W3013953822 hasConceptScore W3013953822C2777612814 @default.
• W3013953822 hasConceptScore W3013953822C2778000748 @default.
• W3013953822 hasConceptScore W3013953822C2778074680 @default.
• W3013953822 hasConceptScore W3013953822C2780334268 @default.
• W3013953822 hasConceptScore W3013953822C2780493683 @default.
• W3013953822 hasConceptScore W3013953822C2780973058 @default.
• W3013953822 hasConceptScore W3013953822C42219234 @default.
• W3013953822 hasConceptScore W3013953822C43791021 @default.
• W3013953822 hasConceptScore W3013953822C548259974 @default.
• W3013953822 hasConceptScore W3013953822C71924100 @default.
• W3013953822 hasConceptScore W3013953822C85663871 @default.
• W3013953822 hasLocation W30139538221 @default.
• W3013953822 hasOpenAccess W3013953822 @default.
• W3013953822 hasPrimaryLocation W30139538221 @default.
• W3013953822 hasRelatedWork W1575634222 @default.
• W3013953822 hasRelatedWork W1601870808 @default.
• W3013953822 hasRelatedWork W2041445418 @default.
• W3013953822 hasRelatedWork W2053931615 @default.
• W3013953822 hasRelatedWork W2073130266 @default.
• W3013953822 hasRelatedWork W2115204657 @default.
• W3013953822 hasRelatedWork W2185825675 @default.
• W3013953822 hasRelatedWork W2312614709 @default.
• W3013953822 hasRelatedWork W2333480519 @default.
• W3013953822 hasRelatedWork W2378079522 @default.
• W3013953822 hasRelatedWork W2385778852 @default.
• W3013953822 hasRelatedWork W2397257879 @default.
• W3013953822 hasRelatedWork W2411941531 @default.
• W3013953822 hasRelatedWork W2468828794 @default.
• W3013953822 hasRelatedWork W2895248757 @default.
• W3013953822 hasRelatedWork W2901323197 @default.
• W3013953822 hasRelatedWork W2920987604 @default.
• W3013953822 hasRelatedWork W2992338884 @default.
• W3013953822 hasRelatedWork W3007799672 @default.
• W3013953822 hasRelatedWork W2182354493 @default.
• W3013953822 isParatext "false" @default.
• W3013953822 isRetracted "false" @default.
• W3013953822 magId "3013953822" @default.
• W3013953822 workType "dissertation" @default.